VIP236 is a small molecule drug conjugate (SMDC). SMDCs are a type of medicine that combines two or more components to create a powerful and targeted treatment. They are designed to target specific cells or proteins in the body, such as those involved in diseases like cancer. By delivering the right ingredients directly to the target, small molecule drug conjugates can potentially improve treatment outcomes and reduce side effects for patients.
VIP236 is currently in a Phase 1 dose escalation study for patients with advanced solid tumors.